Table 2. Distribution of patients according to organ involvement.

<table>
<thead>
<tr>
<th>Organ involvement</th>
<th>Number (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary sclerosing cholangitis</td>
<td>1 (1.4)</td>
</tr>
<tr>
<td>Musculoskeletal</td>
<td>1 (1.4)</td>
</tr>
<tr>
<td>Submandibular gland</td>
<td>1 (1.4)</td>
</tr>
<tr>
<td>Central nervous system</td>
<td>1 (1.4)</td>
</tr>
<tr>
<td>Multisystem involvement</td>
<td>9 (12.8%)</td>
</tr>
</tbody>
</table>

**Figure 1. Right eye proptosis**

**Figure 2. CT abdomen showing hydronephrosis due to retroperitoneal fibrosis**

**Disclosure of Interests:** None declared

**AB1031**

**DYSKERATOTIC CELLS IN PERSISTENT PRURITIC SKIN LESIONS AS A PROGNOSTIC FACTOR IN ADULT-ONSET STILL’S DISEASE.**

S. Inotani1, Y. Taniguchi1, H. Nishikawa1, N. Maeda-Aoyama1, K. Nakajima1, K. Ani2, Y. Terada1, Kochi Medical school Hospital, Kochi-city, Japan; 1Kochi Red Cross Hospital, Kochi-city, Japan

**Background:** Adult-onset Still’s disease (AOSD), a systemic inflammatory disorder, is characterized by high fever, evanescent rash, arthritis, and hyperferritinaemia. AOSD is also reported to be associated with other skin lesions, including persistent pruritic papules and plaques.

**Objectives:** This study aimed to assess the significance of dyskeratotic skin lesions in Japanese AOSD patients.

**Methods:** We retrospectively assessed the histology of persistent pruritic skin lesions and evanescent rashes and the relationship between dyskeratotic cells, serum markers, and outcomes in 20 Japanese AOSD patients, comparing AOSD histology with that of dermatomyositis (DM), drug eruptions, and graft-versus-host disease (GVHD).

**Results:** Persistent pruritic lesions were characterized by scattered single keratinocytes with an apoptotic appearance confined to the upper layer of the epidermis and horny layer without inflammatory infiltrate. In contrast to AOSD, the histology of DM, drug eruption, and GVHD demonstrated dyskeratotic cells in all layers of the epidermis with inflammatory infiltrate. AOSD with evanescent rash showed no dyskeratotic cells. The dyskeratotic cells in pruritic AOSD lesions stained positive for ssDNA and terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling, indicating apoptosis. Serum IL-18 was significantly higher in AOSD patients with dyskeratotic cells than those without, and generally required higher doses of glucocorticoids, immunosuppressants, and biologic agents. Two of ten AOSD patients with dyskeratotic cells died from haemophagocytic lymphohistiocytosis.

**Conclusion:** Persistent pruritic AOSD skin lesions are characterized by dyskeratotic cells with apoptotic features, involving the upper layers of the epidermis. There may be a link to elevated IL-18. This dyskeratosis may be a negative prognostic indicator.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2020-eular.4072

**AB1032**

**CONTRIBUTION OF BONE BIOPSY DURING REVELATORY BONE METASTASES**

S. Jnri1, M. Ben Majdouba1, S. Ben Jamaa1, A. Feki1, R. Akrout1, M. Ezzeddine1, M. H. Kallel1, H. Fourati1, S. Baklouti1, Hedi Chaker Hospital, Sfax, Tunisia

**Background:** Bone metastases (BM) are tumor cells that originate in a primary malignant tumor and are localized remotely in bone tissue. They may or less faithfully reproduce the morphological and biological characteristics of the primary tumor. Histological analysis is essential to confirm the diagnosis of BM and to identify the primary tumor if possible and sometimes to help in the selection of treatment.

**Objectives:** The aim of this work is to study the contribution of bone biopsy during revealing BM in diagnostic strategy and therapeutic decision.

**Methods:** We retrospectively studied the files of 105 patients hospitalized in a Rheumatology department of for BM revealing from January 2000 until December 2015. For each patient we collected epidemioclinical and anatomo pathological data to arrive at the diagnosis of primary neoplasm and histological type.

**Results:** The patients were divided into 86 men (81.9%) and 19 women (18.1%) with a sex ratio (M / F) of 4.52. The average age of our patients was 64.9 ± 13.29 years. Pain was the most frequent reason for consultation found in 97.1%. This pain was either of bone site (61.9%) or of radiacular topography (41.9%). Bone swelling or a pathological fracture revealed BM in 4.8% and 8.6% of the cases, respectively. The onset of neurological damage was noted in 13.3% of the cases. Histologically, the bone biopsy performed in 64 patients made it possible to specify the histological type (carcinoma, adenocarcinoma) in 64% of the cases and to lead to primary cancer in 57.8%. A non-radio-guided percutaneous bone biopsy was performed in 44 patients (68.75%) including 41 osteo-medullary biopsy in iliac crest (BOM) and 3 in the sternum, a bone biopsy directed under scanner in 16 cases (25%) and a surgical bone biopsy in 4 cases.

**Conclusion:** Thanks to improved sampling and immunohistochemistry techniques, the precise histological type and location of the primary tumor could be identified, thereby improving the quality of care for patients with increased life expectancy.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2020-eular.6285

**AB1034**

**DEPRESSION AND ANXIETY IN FAMILIAL MEDITERRANEAN FEVER**

D. Karatas1, Z. Öztürk1, D. Çekic2, Z. Yurtseven2, Ü. Erkorkmaz2, E. Gönlütü1, 1Sakarya University, Internal Medicine/Rheumatology, Sakarya, Turkey; 2Sakarya University, Internal Medicine, Sakarya, Turkey; 3Sakarya University, Biostatistics Department, Sakarya, Turkey

**Background:** Familial Mediterranean Fever (FMF) is a hereditary autoinflammatory disease characterized by recurrent attacks of fever, peritonitis, pleuritis, arthritis, and skin eruption (1). It is shown by studies that chronic diseases like diabetes mellitus, chronic heart disease, hypertension which other than inflammatory rheumatologic disease increase depression and anxiety (2). There are a few studies evaluating depression and anxiety in FMF patients, and these results are conflicting (3,4).
AB1035

INTESTINAL MICROBIOTA COMPOSITION OF ADULT PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER AND HEALTHY CONTROLS (THE RHEUMA-BIOTA STUDY)

N. S. Yasar Bilge1, V. Perez Brocal2, T. Kasifoglu1, U. Bilge1, N. Kasifoglu1, A. Moya3, E. O. Dineyici4, Eskisehir Osmangazi University Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Eskisehir, Turkey; 1Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana, Valencia, Spain; 2Eskisehir Osmangazi University Faculty of Medicine, Department of Family Medicine, Eskisehir, Turkey; 3Eskisehir Osmangazi University Faculty of Medicine, Department of Microbiology, Eskisehir, Turkey; 4Integrative Systems Biology Institute (IBSybio), University of Valencia and Spanish Research Council (CSIC), Valencia, Spain; 5Foundation for the Promotion of Sanitary and Biomedical Research of Valencia Community (FISABIO), Valencia, Spain; 6Eskisehir Osmangazi University Faculty of Medicine, Department of Pediatrics, Eskisehir, Turkey

Background: Although Familial Mediterranean Fever (FMF) is a monogenic disease, microbiota composition may play role in the pathogenesis or phenotypic expression.

Objectives: We aim to evaluate the intestinal microbiota composition in patients with FMF and to compare with healthy controls.

Methods: In this prospective cohort study, a group of 10 adult patients with FMF and 10 age-appropriate healthy controls, for which there was strict inclusion/exclusion, were enrolled. Fecal samples were stored at -80°C until DNA extraction. A region of the 16S rRNA gene (V3-V4) was selected and sequencing was performed on the Illumina MiSeq platform at the Sequencing and Bioinformatics Service of FISABIO foundation.

Results: Alpha and beta diversity tests were similar between FMF and control groups except that Chao1 index. Chao1 index was modestly decreased in FMF group comparing the healthy controls (p=0.05). Our results showed differences in the intestinal microbiota composition of patients with FMF, with a higher abundance of Eggertihella, at genus level. At species level, Eggertihella sinensis and Eggertihella lenta were more abundant in patients with FMF.

Conclusion: Eggertihella lenta was previously shown to be higher in type II diabetes, multiple sclerosis, rheumatoid arthritis and some disseminated infections. In this study we firstly showed abundance of Eggertihella in patients with FMF, especially in E. sinensis and E. lenta; in addition to. Whether any of observed associations are causal, or the direction of causality is unclear yet and further studies with patients with FMF at the first diagnosis might clarify this issue.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.5852

AB1036

CLINICAL MANIFESTATIONS, CLINICAL COURSE, AND OUTCOMES OF IMMUNOGLOBULIN G4 RELATED DISEASE

W. Katchamart1, K. Phaprapaph2, P. Ngamjanyaporn3, P. Narongroeknawin4, N. Kasitason5, Division of Rheumatology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; 2Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; 3Division of Rheumatology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; 4Division of Rheumatology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; 5Division of Rheumatology, Department of Medicine, Faculty of Medicine Phramongkutklao Hospital, Phramongkutklao College of Medicine, Bangkok, Thailand; 6Division of Rheumatology, Department of Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; 7Division of Rheumatology, Department of Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand

Background: Immunoglobulin G4 related disease (IgG4-RD) is an uncommon chronic systemic autoimmune disease, pathologically characterized by lymphoplasmacell cell, IgG4 plasma cell or storiform fibrosis infiltration with elevated serum IgG4 level. IgG4-RD is a new disease and not widely recognized.

Objectives: The aim of this study was to describe clinical manifestations and outcomes of IgG4-RD in Thai patients

Methods: This multicenter retrospective cohort study included patients who aged ≥ 18 years and were diagnosed with IgG4-RD according to 2011 comprehensive or consensus diagnostic criteria, between 2000 and 2019 in four academic centers in Thailand. Baseline characteristic, laboratory and pathologic findings, treatments, and outcomes were systematically recorded.

Results: Of the 110 patients included, 71% were male with mean age (SD) of 59.6 (13.3) years and median disease duration (IQR) of 28.8 (14.6-53.5) months. Single organ involvement was observed in 60 patients (54.5%). The most common presenting organ involvement was the orbit (29%), followed by the salivary glands (19%), lacrimal glands (18%), bile duct (16%), and pancreas (11%). The most frequently affected organs were the orbits (34%), followed by the salivary glands (26%), lacrimal glands (20%), bile duct (16%), and lymph nodes (19%). Ninety-six percent (96%) had IgG4 level of more than 135 mg/dl at presentation. Most patients (92%) were treated with corticosteroid (CS) alone or in combination with immunosuppressive agents. Azathioprine (47%) and methotrexate (11%) were the most commonly used immunosuppressive agents. Additionally, 20% required surgery, and 6.4% underwent stent insertion. One-fourth (26%) were in remission with successful CS tapering, while 37%, and 29% had complete, and partial response. Nevertheless, 22% relapsed with median time to relapse (IQR) of 22.2 (12.8-41.1) months. Relapse was common in patients with orbital (p = 0.001) and lung (p=0.007) involvement, and patients with longer disease duration (median 44.1 and 23.1 months, P=0.001), while serum IgG4 level was insignificantly higher in relapse group (median 1,085 vs. 850 mg/dL, p=0.28).

Conclusion: IgG4-RD is a chronic systemic autoimmune disease with diverse manifestations, response to treatment, and outcomes. Most patients responded well to CS and immunosuppressive agents with notable relapse rate, while minority required surgery or mechanical intervention.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.3906

AB1037

CANAKINUMAB FOR TREATMENT OF ADULT ONSET STILLS’ DISEASE-RESULTS OF THE 24 WEEK TREATMENT AND BEYOND: A MULTI-CENTRE, PLACEBO-CONTROLLED STUDY (CONSIDER)

C. Kecd1, J. Listing2, J. Zernicke1, A. Weiß2, F. Behrens3, N. Blank4, J. Henes5, J. Kekow6, A. Rubbert-Roth7, H. Schulze-Koops8, E. Seipelt9, C. Specker10, J. Kekow6, A. Rubbert-Roth7, H. Schulze-Koops8, E. Seipelt9, C. Specker10

Background: Canakinumab for adult onset Still’s disease (AOSD) is an interleukin-1 beta (IL-1β) receptor antagonist, approved for treatment of active AOSD refractory to conventional treatments, with a mean disease duration of more than 2 years and at least one systemic manifestation. The purpose of our study was to assess the clinical activity, safety and tolerability of canakinumab in patients with active clinical symptoms of AOSD.

Objectives: The primary objective of the study was to assess the proportion of patients achieving clinical remission (CR) at week 24 in patients with AOSD. The secondary objectives were to assess the proportion of patients achieving partial remission (PR), stable disease (SD), minimal residual disease (MRD), and flare at week 24; to assess the proportion of patients achieving remission or PR at week 24; and to evaluate the safety and tolerability of canakinumab.

Methods: This randomized, double-blind, placebo-controlled, multi-center, parallel-group, phase 3 study enrolled patients with AOSD who had active clinical symptoms despite conventional treatment with at least one systemic manifestation. Patients were randomized 1:1 to receive subcutaneous canakinumab 150 mg or placebo every 2 weeks for 24 weeks. The primary endpoint was the proportion of patients achieving CR at week 24.

Results: A total of 102 patients were enrolled and 94 patients were evaluable for the primary endpoint. At week 24, 43.8% of patients achieved CR with canakinumab compared to 1.1% with placebo (p < 0.001). The most frequent adverse events were nasopharyngitis (27%) and nasopharyngitis with cough (14%). No serious adverse events were reported. All adverse events were considered to be unrelated to the study drug.

Conclusion: Canakinumab was effective and well tolerated in patients with AOSD. The proportion of patients achieving CR at week 24 was significantly higher with canakinumab compared to placebo. Further studies are needed to evaluate the long-term efficacy and safety of canakinumab in patients with AOSD.